Prostate Cancer in the Elderly

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2005 Dec 20

PMID 16362603

Citations 2

Authors

Hatzimouratidis Konstantinos

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the second leading cause of cancer deaths among men. Despite earlier diagnosis due to prostate specific antigen (PSA) screening, it is still a disease of the elderly. Diagnosis is based on digital rectal examination (DRE) and PSA assessment. Refinements in PSA testing (age-specific reference ranges, free PSA, PSA density and velocity) increased specificity and limited unnecessary prostate biopsies. Diagnosis in earlier stages (T1 and T2) commonly leads to cure with current treatment modalities. These include radical prostatectomy, external beam radiotherapy and brachytherapy. Other treatment options under development include cryotherapy and high-intensity focused ultrasound. Metastatic prostate cancer is incurable and treatment is based on hormonal therapy. Cytotoxic chemotherapy has only limited role in hormone-independent prostate cancer. Radioisotopes and biphosphonates may alleviate bone pain and prevent osteoporosis and pathological fractures. Follow-up is based on PSA. Prognostic factors for recurrence include stage, Gleason score, pre- and posttreatment PSA. Quality of life issues play an important role in selecting treatment, especially in the elderly due to comorbidities that may negatively affect the overall quality of life. A holistic approach is recommended addressing all quality of life issues without focus only in cancer control.

Citing Articles

Exercise as a prescription for patients with various diseases.

Luan X, Tian X, Zhang H, Huang R, Li N, Chen P J Sport Health Sci. 2019; 8(5):422-441.

PMID: 31534817 PMC: 6742679. DOI: 10.1016/j.jshs.2019.04.002.

Screening for prostate cancer: a controversy or fact.

Stavridis S, Saidi S, Lekovski L, Dohcev S, Spasovski G Hippokratia. 2010; 14(3):170-5.

PMID: 20981165 PMC: 2943354.

References

Liepe K, Runge R, Kotzerke J . The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2004; 131(1):60-6. DOI: 10.1007/s00432-004-0625-0. View

Crook J, Lukka H, Klotz L, Bestic N, Johnston M . Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ. 2001; 164(7):975-81. PMC: 80925. View

Wolf Jr J, Cher M, DallEra M, Presti Jr J, Hricak H, Carroll P . The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995; 153(3 Pt 2):993-9. View

Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta K . Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1998; 50(6):920-8. DOI: 10.1016/S0090-4295(97)00459-7. View

Harris K, Reese D . Treatment options in hormone-refractory prostate cancer: current and future approaches. Drugs. 2002; 61(15):2177-92. DOI: 10.2165/00003495-200161150-00003. View

Tyrrell C, Kaisary A, Iversen P, Anderson J, Baert L, Tammela T . A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998; 33(5):447-56. DOI: 10.1159/000019634. View

Zelefsky M, Fuks Z, Hunt M, Lee H, Lombardi D, Ling C . High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001; 166(3):876-81. View

Catalona W, Smith D, Wolfert R, Wang T, Rittenhouse H, Ratliff T . Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995; 274(15):1214-20. View

Zietman A, Coen J, Dallow K, Shipley W . The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995; 32(2):287-92. DOI: 10.1016/0360-3016(95)00123-G. View

10.

Okihara K, Cheli C, Partin A, Fritche H, Chan D, Sokoll L . Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002; 167(5):2017-23; discussion 2023-4. DOI: 10.1016/s0022-5347(05)65075-6. View

11.

Mettlin C, Murphy G, Lee F, Littrup P, Chesley A, Babaian R . Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer. 1993; 72(5):1701-8. DOI: 10.1002/1097-0142(19930901)72:5<1701::aid-cncr2820720534>3.0.co;2-e. View

12.

Beyer D, Brachman D . Failure free survival following brachytherapy alone for prostate cancer: comparison with external beam radiotherapy. Radiother Oncol. 2000; 57(3):263-7. DOI: 10.1016/s0167-8140(00)00286-3. View

13.

Kemp P, Maguire G, Bird N . Which patients with prostatic carcinoma require a staging bone scan?. Br J Urol. 1997; 79(4):611-4. DOI: 10.1046/j.1464-410x.1997.00121.x. View

14.

Schroder F, Collette L, de Reijke T, Whelan P . Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer. 2000; 82(2):283-90. PMC: 2363280. DOI: 10.1054/bjoc.1999.0916. View

15.

Zincke H, Oesterling J, Blute M, Bergstralh E, Myers R, Barrett D . Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994; 152(5 Pt 2):1850-7. DOI: 10.1016/s0022-5347(17)32399-6. View

16.

Elghany N, Schumacher M, Slattery M, West D, Lee J . Occupation, cadmium exposure, and prostate cancer. Epidemiology. 1990; 1(2):107-15. DOI: 10.1097/00001648-199003000-00005. View

17.

Pinski J, Dorff T . Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur J Cancer. 2005; 41(6):932-40. DOI: 10.1016/j.ejca.2004.12.026. View

18.

Benson M, Whang I, Pantuck A, Ring K, Kaplan S, Olsson C . Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992; 147(3 Pt 2):815-6. DOI: 10.1016/s0022-5347(17)37393-7. View

19.

Nag S, Beyer D, Friedland J, Grimm P, Nath R . American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44(4):789-99. DOI: 10.1016/s0360-3016(99)00069-3. View

20.

Moinpour C, Savage M, Troxel A, Lovato L, Eisenberger M, Veith R . Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. J Natl Cancer Inst. 1998; 90(20):1537-44. DOI: 10.1093/jnci/90.20.1537. View